Notably, NU-0129, composed of siRNA targeting the GBM oncogene Bcl2Like12 (Bcl2L12) and a gold nanoparticle core, was the first spherical nucleic acid (SNA) drug administered systemically.370 The Phase 0 clinical study (NCT03020017) in eight patients with GBM showed that NU-0129 could pass through the BBB and accumulate in tumors, reducing the abundance of BCL2L12 protein and demonstrating its potential as an innovative therapy for GBM.371. The gene discussed is BCL2L12; the disease is glioblastoma.